Is KMDA or KPRX more undervalued in 2026?

CirclFi compares Kamada Ltd. (KMDA) and Kiora Pharmaceuticals, Inc. (KPRX) using 13 institutional-grade valuation models. KMDA has a Quality of Company score of 1.9/10 while KPRX scores 5.5/10.

Which is a better buy — KMDA or KPRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do KMDA and KPRX valuations compare?

KMDA at $7.81 and KPRX at $2.68 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

KMDA vs KPRX Valuation Comparison 2026 — Intrinsic Value Analysis

KMDA

Pharmaceutical Preparations

Kamada Ltd.

Quality

1.9

out of 10

Value Trap

—

Price

$7.81

Last close

Models

11/13

Active

KPRX

Pharmaceutical Preparations

Kiora Pharmaceuticals, Inc.

Quality

5.5

out of 10

Value Trap

LOW

Price

$2.68

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	KMDA Fair Value	KMDA Upside	KPRX Fair Value	KPRX Upside
Bayesian DCF	Intrinsic	$2.08	-73.4%	$2.01	-24.8%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$3.86	-53.3%	—	—
ML-RIV	Intrinsic	$6.70	-14.2%	$0.48	-80.2%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for KMDA vs KPRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KMDA vs KPRX — Which Stock Is More Undervalued?

KPRX scores higher with a 5.5/10 quality rating vs KMDA's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Kamada Ltd. (KMDA) and Kiora Pharmaceuticals, Inc. (KPRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KMDA currently trades at $7.81 with a QOC of 1.9/10, while KPRX trades at $2.68 with a QOC of 5.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).